Here are some questions from our live presentation:
Q: Can you recomend a specific QA monitoring procedure for CSP's to meet 797 guidelines?
Q: Is there a requirement to do end product testing on sterile products that are manipulated in a 797 compliant IV room using 797 B.U.D. recomendated dating?
Q: Any general rule of thumb to determine the number of units compounded before testing and how many?
Q: Do you consider repacking fentanyl into syringes or vials a low or medium risk procedure?
